Seeking Alpha

Amar Singh's  Instablog

Amar Singh
Send Message
Part time Long trader
My blog:
My Trading Diary
  • LJPC A Hidden Gem Found By Baker Bros And Reason Why They May Have Liked It  1 comment
    Oct 23, 2013 7:17 AM | about stocks: LJPC

    Only reason LJPC got attention was the Unique name Bakers Bros.

    The genius and wise brothers chose a .07 cents stock ?

    Why will they do that ? I asked myself and I found answer in myself.

    May be they thought LJPC trial can be a breakthrough and it has potential.

    What if they are wrong ? My answer is No one is perfect except Almighty .

    It is also true that God created every human being mind unique and special

    And it is possible if Baker brothers have so much success in biotech stocks , it is for two reasons , one is they are very intelligent and second is God has his grace on them .

    Now don not think I am bringing Almighty in biotech stocks, It's my personal belief and I think

    I chose to invest my Roth IRA 's 10% portfolio which is speculative money in it.

    By investing speculative money aka Vegas money , I am not worried for near term ups and down since I will be waiting for March 2014 Phase 2 results.

    It can go back to zero or it can go to one dollar or more, I have no particular target .

    About Chronic Kidney Disease

    Chronic kidney disease ("CKD") currently affects 14% of Americans or approximately 49 million people. The United States Renal Data System, 2012 Annual Data Report, states that in 2010, costs for CKD reached $41 billion for Medicare alone. Overall per person per year costs for CKD were estimated at $22,323 for Medicare patients of age 65 and older and $13,395 for patients of age 50-64. Patients with CKD may progress to end-stage renal disease ("ESRD"). According to the National Institute of Diabetes and Digestive and Kidney Diseases as of 2008, there were 547,982 individuals in the US under treatment for ESRD and 88,630 deaths per year from ESRD.

    Recent Accomplishments

    Granted Orphan Drug Designation by the FDA for LJPC-6417 (April 18, 2013)

    Filed IND for LJPC-501 in hepatorenal syndrome with FDA (June 4, 2013)

    Achieved positive results in the Phase 1 trial with GCS-100 in CKD (June 6, 2013)

    Received acceptance from the FDA of the IND for LJPC-501 in HRS (July 2, 2013)

    Initiated Phase 2 clinical trial of GCS-100 for the treatment of CKD (July 8, 2013)

    Granted Orphan Drug Designation by the FDA for LJPC-0712 in NP-C (July 17, 2013)

    About GCS-100

    GCS-100 is a complex polysaccharide derived from pectin that binds to, and blocks the activity of, galectin-3, a type of galectin. Over-expression of galectin-3 has been implicated in a number of human diseases, including chronic organ failure and cancer. This makes modulation of the activity of galectin-3 an attractive target for therapy in these diseases.

    About LJPC-501

    LJPC-501 is a peptide agonist of the renin-angiotensin system that acts to help the kidneys balance body fluids and electrolytes. Studies have shown that LJPC-501 may improve renal function in patients with HRS

    Oct 1, 2013 Baker Bros. participated in a recent $10 MM financial restructuring and private placement for La Jolla, and accumulated 14.9 MM shares of common stock and 2,426 shares of Series F preferred stock. This is equivalent to a newly established $3.5 MM overall investment in La Jolla Pharmaceutical Company.

    October 25, 2013 LJPC announced the appointment of existing independent director, Mr. Saiid Zarrabian, as Chairman of the Board. The company now has 3 independent directors, as required for listing on major stock exchanges.

    October 27, 2013 LJPC announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application number 13/888,305 covering compositions of modified pectin. The patent, which expires in 2025 without taking into account patent term extension, provides proprietary protection for colloidal pectin solutions comprised of purified, modified pectin substantially free of molecular weights below 25 kD.

    Disclosure: I am long OTC:LJPC.

    Additional disclosure: Bakers bros also have position XOMA, IDRA , ACAD , PCYC , SGEN

    Themes: XOMA, IDRA , ACAD , PCYC , SGEN Stocks: LJPC
Back To Amar Singh's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • bdwight1
    , contributor
    Comments (33) | Send Message
     
    Looks like an interesting speculation. However, I'm always concerned when I see a micro-cap with a huge number of shares issued, in LJCP's case 220M+ shares. If the drug trials are successful and there are secondary share raises we could see 400M+ shares issued in this company.

     

    In your opinion, is the share count here an issue for investors or should we just focus on trial results? Does this 'excessive' share issuance indicate management doesn't have a good grip on the financial structure of the company?

     

    Thx for your response.
    1 Jan 2014, 11:21 AM Reply Like
Full index of posts »
Latest Followers

StockTalks

  • IDRA Next Multi Bagger In My Roth IRA , Baker Bros Love It , So We Need To Do Same $IDRA http://seekingalpha.com/p/23w71
    Dec 10, 2014
  • $BIOD BIOD nice volume today on weekend presentation and PDUFA is 10/30/2010 so presentation should give more BOOST to speculators
    Jun 24, 2010
  • bought 200 shares 21.16 with 20 PUT as hedge for 1.30 AFFY
    Jun 11, 2010
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.